{"entity":{"id":"nct06973564","kind":"trial","name":"JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration","aka":[],"tldr":"A phase 1/2 trial of JAB-23E73 in advanced solid tumours, run by Jacobio Pharmaceuticals Co., Ltd., now recruiting.","summary":"JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration is a phase 1/2 interventional study registered as NCT06973564 by Jacobio Pharmaceuticals Co., Ltd., with 294 participants planned, started 2025-05-29 and due to reach its primary completion in 2027-11. Interventions recorded: JAB-23E73.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06973564","url":"https://clinicaltrials.gov/study/NCT06973564"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06973564","phase":"1/2","setting":"A Phase 1/2a, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of JAB-23E73 in Adult Patients With Advanced Solid Tumors With KRAS Alteration","sponsor":"Jacobio Pharmaceuticals Co., Ltd.","enrolled":294,"outcomes":[]},"route":"/trials/nct06973564/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"jacobio-pharmaceuticals","kind":"company","name":"Jacobio Pharmaceuticals","route":"/companies/jacobio-pharmaceuticals/"}]}}